Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update

Immix Biopharma, Inc. (NASDAQ:IMMX) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 289,700 shares, an increase of 35.6% from the May 15th total of 213,600 shares. Based on an average daily volume of 196,400 shares, the short-interest ratio is presently 1.5 days. Currently, 1.8% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Immix Biopharma in a research report on Wednesday, June 4th.

Immix Biopharma Price Performance

Immix Biopharma stock opened at $2.39 on Thursday. The stock’s 50 day moving average price is $2.05 and its 200 day moving average price is $1.98. Immix Biopharma has a 1-year low of $1.26 and a 1-year high of $3.00. The company has a market cap of $66.63 million, a PE ratio of -3.41 and a beta of 0.31.

Immix Biopharma (NASDAQ:IMMX) last released its earnings results on Monday, March 24th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09. On average, equities research analysts anticipate that Immix Biopharma will post -0.87 EPS for the current fiscal year.

Institutional Trading of Immix Biopharma

An institutional investor recently bought a new position in Immix Biopharma stock. SBI Securities Co. Ltd. bought a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 17,500 shares of the company’s stock, valued at approximately $38,000. SBI Securities Co. Ltd. owned approximately 0.06% of Immix Biopharma at the end of the most recent quarter. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.